Contract notice
Section I: Contracting
authority
I.1) Name and addresses
NHS Bradford City CCG
Bowling Mills
Bradford
BD5 7JR
UK
Telephone: +44 1274237290
E-mail: james.allen.procurement@gmail.com
NUTS: UKE4
Internet address(es)
Main address: www.bradfordcityccg.nhs.uk
I.3) Communication
The procurement documents are available for unrestricted and full direct access, free of charge at:
www.nhssourcing.co.uk
Additional information can be obtained from the abovementioned address
Tenders or requests to participate must be sent electronically to:
www.nhssourcing.co.uk
Tenders or requests to participate must be sent to the abovementioned address
I.4) Type of the contracting authority
Body governed by public law
I.5) Main activity
Health
Section II: Object
II.1) Scope of the procurement
II.1.1) Title
NHS Bradford CCGs Medicines Optimisation.
II.1.2) Main CPV code
85100000
II.1.3) Type of contract
Services
II.1.4) Short description
The aim of the service is to review the use of medicines for patients with complex care needs being prescribed multiple medicines to ensure they are receiving ‘appropriate polypharmacy’.
Appropriate polypharmacy is defined as ‘prescribing for an individual for complex conditions or for multiple conditions in circumstances where medicine use has been optimised and where the medicines are prescribed according to best evidence’.
II.1.5) Estimated total value
Value excluding VAT:
1 200 000.00
GBP
II.1.6) Information about lots
This contract is divided into lots:
No
II.2) Description
II.2.3) Place of performance
NUTS code:
UKE4
II.2.4) Description of the procurement
The aim of the service is to review the use of medicines for patients with complex care needs being prescribed multiple medicines to ensure they are receiving ‘appropriate polypharmacy’.
Appropriate polypharmacy is defined as ‘prescribing for an individual for complex conditions or for multiple conditions in circumstances where medicine use has been optimised and where the medicines are prescribed according to best evidence’.
Polypharmacy is a term generally understood to refer to the concurrent use of multiple (usually 4 or more) medications by 1 individual. Polypharmacy is widespread and increasingly common occurring in primary and secondary care and in care homes. The occurrence of polypharmacy has risen dramatically over the last few decades driven by:
1) The growth of an ageing and increasingly frail population.
2) The increasing prevalence of multi-morbidity, where patients may be living with several long-term conditions often compounded by disability and/or frailty.
3) The increasing use of technology and technologically advanced medicine, which means that a greater number of conditions can be treated medically.
4) Guidelines driven prescribing.
Polypharmacy is not an issue exclusively related to older people and it is important that medication reviews are undertaken regularly, especially for the higher risk patients to ensure that their medication regime is appropriate to their needs and that the perspective of the patient is taken into account when taking multiple medicines.
Medicines optimisation is a significant issue facing many healthcare economies as ‘polypharmacy’ becomes an increasingly widespread and common issue. There is growing evidence that medicines use is sub-optimal in a number of patient pathways. Sub-optimal medicines use leads to poorer patient experiences and outcomes and the financial waste of limited resources. It can also place increasing pressure on the urgent and emergency care system as patients may be admitted for non-adherence or adverse drug reactions.
II.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
II.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start:
01/04/2017
End:
31/03/2020
This contract is subject to renewal: Yes
Description of renewals:
2 potential extensions of 1 year each.
II.2.9) Information about the limits on the number of candidates to be invited
II.2.10) Information about variants
Variants will be accepted:
No
II.2.11) Information about options
Options:
No
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Section IV: Procedure
IV.1) Description
IV.1.1) Type of procedure
Open procedure
IV.1.8) Information about Government Procurement Agreement (GPA)
The procurement is covered by the Government Procurement Agreement:
Yes
IV.2) Administrative information
IV.2.2) Time limit for receipt of tenders or requests to participate
Date:
01/12/2016
Local time: 12:00
IV.2.4) Languages in which tenders or requests to participate may be submitted
EN
IV.2.6) Minimum time frame during which the tenderer must maintain the tender
Duration in months: 6 (from the date stated for receipt of tender)
IV.2.7) Conditions for opening of tenders
Date:
01/12/2016
Local time: 13:00
Place:
Electronically, via www.nhssourcing.co.uk
Section VI: Complementary information
VI.1) Information about recurrence
This is a recurrent procurement:
No
VI.4) Procedures for review
VI.5) Date of dispatch of this notice
28/10/2016